9 Things You Should Know About Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

Share on FacebookTweet about this on TwitterShare on Google+Share on RedditShare on LinkedInPrint this pageEmail this to someone

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been going through tough times. However investors had something to cheer after four brokerages have given buy rating to companies stock.

So what happened at Valeant Pharmaceuticals Intl Inc (NYSE:VRX) over last few days

1) Company announced numbers for Q1. However, Stifel states that the updated guidance provided by the company is conservative in nature with no upside.

2) Profit misses estimates, Downward revisions below

3) Sequoia Fund exits its stake in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) while Andrew Left of Citron Research buys shares for short-term.

4) Bill Ackman becomes largest shareholder

5) Company avoids default on bonds

6) Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s bonds have become a buy, According to JPMorgan Chase & Co. (NYSE:JPM)

7) CEO Joseph Papa has a lot to do to turnaround things. The margin of error for him is very narrow considering the expectations of Investors.

8) Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is also looking to restructure its deal with Walgreens after Financial Times reports that the company is losing on the drugs sold through drugstore. If things don’t improve then there are chances of the company cancelling the agreement altogether. The deal was entered last year after its relationship with philidor ended over accounting scandal.

9) Coming 6 months will be very critical for Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in order to make an impact.

It remains to be seen if Valeant Pharmaceuticals Intl Inc (NYSE:VRX) can become darling of investors again or not? Also, the role Bill Ackman plays in restructuring of the beleaguered entity. Billionaire Investor Carl Icahn has categorically stated that he will not invest in Valeant.

Viraj Shah

Viraj Shah has completed M.Com (Finance) and is currently pursuing his CFP. He tracks US markets along with other global markets like India very closely. He is very passionate about stocks, real estate, and technology. He also believes that money can always be made in the market.

You may also like...

Read previous post:
Valeant VRX
Margin for Error Gets Much More Narrow for Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

It doesn't take a genius to see that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) had a disappointing quarter. The real question...

Close